Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.54 |
| ▸ | PDE5A | O76074 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 4/20 | 0.48 |
| ▸ | USP1 | O94782 | 5/20 | 0.46 |
| ▸ | WDR48 | Q8TAF3 | 5/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | SELE | P16581 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5129639 | 0.89 | USP1 (0.45) | APPPDE5AESR1USP1WDR48 | |
| SCHEMBL5127810 | 0.86 | USP1 (0.50) | APPPDE5AESR1USP1WDR48 | |
| SCHEMBL5129285 | 0.83 | APP (0.61) | APPPDE5AESR1ICAM1SELE | |
| SCHEMBL5121621 | 0.83 | PDE5A (0.48) | PDE5AEGFR | |
| SCHEMBL5114669 | 0.81 | ICAM1 (0.66) | APPPDE5AESR1ICAM1SELE | |
| SCHEMBL5120111 | 0.81 | ACHE (0.47) | APPPDE5A | |
| SCHEMBL7013493 | 0.81 | APP (0.58) | APPPDE5AESR1ICAM1SELE | |
| SCHEMBL5121710 | 0.81 | PDE5A (0.59) | PDE5AUSP1WDR48 | |
| SCHEMBL5118687 | 0.80 | USP1 (0.52) | PDE5AUSP1WDR48 | |
| SCHEMBL5122246 | 0.80 | USP1 (0.45) | PDE5AUSP1WDR48EGFRPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| CN-1875023-A | Use of thienopyrimidines | MERCK PATENT GMBH (DE) | 2006-12-06 | — | — | CN | disclosed |
| EP-1685136-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047292-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
| EP-0934321-B1 | THIENOPYRIMIDINE WITH PHOSPHODIESTERASE V INHIBITING EFFECT | MERCK PATENT GMBH (DE) | 2003-08-06 | — | — | EP | disclosed |
| US-6432950-B1 | ANTICANCER AGENTS; KILLING CANCER CELLS | CELL PATHWAYS | 2002-08-13 | — | — | US | disclosed |
| US-6133271-A | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6130223-A | Thienopyrimidine with phosphodiesterase V inhibiting effect | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-10-10 | — | — | US | disclosed |
| US-5948911-A | Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 1999-09-07 | — | — | US | disclosed |
| EP-0920431-A1 | THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998006722-A1 | THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | APP 4123/4885PDE5A 2002/4885ESR1 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.